Optimal treatment strategies for metastatic hormone-sensitive prostate cancer (mHSPC) are evolving with novel multimodal approaches. For well-selected patients, early local radiotherapy can play a pivotal role in high-volume mHSPC. Radiotherapy controls local disease, reduces symptoms, and may potentially delay castration resistance, warranting its consideration alongside systemic therapies in high-volume mHSPC.
European urology. 2024 Dec 17 [Epub ahead of print]
Steven Tisseverasinghe, Marwan Tolba, Fred Saad, Karim Fizazi, Boris Bahoric, Tamim Niazi
Department of Radiation Oncology, Gatineau Hospital, McGill University, Gatineau, Canada., Department of Radiation Oncology, Dalhousie University, Halifax, Canada., Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montreal, Canada., Department of Cancer Medicine, Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France., Department of Radiation Oncology, Jewish General Hospital, McGill University, Montreal, Canada., Department of Radiation Oncology, Jewish General Hospital, McGill University, Montreal, Canada. Electronic address: .